Introduction {#Sec1}
============

Rapid advances in the field of lipid nanoparticle formulations (LNFs) have caused a revolution to offer superior drug delivery systems for the mitigation of numerous dreadful diseases particularly in the area of pharmaceutical sciences. Such LNFs employed as potential nanocarriers system provides many merits concerning encapsulating hydrophilic drugs, imparting kinetic stability and rigid structural morphology in comparison with other lipid-based vesicular (liposomes, cationic liposomes, leclplex, etc.) and emulsion (lipid emulsions) colloidal nanocarriers systems. LNFs show low cytotoxicity and possess good production scalability also. Development of a wide variety of LNFs viz., solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), lipid-drug conjugates (LDCs), lipid-polymer hybrid (LPH), etc. for oral drug delivery application has diverted the researcher attention over the years. Apart from these various kinds of LNFs, LDCs attracts increased attention especially in the field of biomedical and pharmaceutical applications. The fundamental vital features of LDCs are the ability of the lipidic matrix to conjugate especially with the water-soluble/hydrophilic drug moieties **(**Fig. [1](#Fig1){ref-type="fig"}**)** that further offers novel pro-drugs especially in oral drug delivery applications for fulfilling many therapeutic outcomes \[[@CR1]\]. Moreover, LDCs technology represents a promising novel approach of controlling and site-specific triggering of the bio-actives of interest. LDCs possess certain advantages like other lipid-based nanocarrier systems, such as \[[@CR2], [@CR3]\].Lipids used for the design of LDCs are biocompatible with the low toxicity profileSolid at both body and room temperature like SLNs and NLCs.High capacity to load hydrophilic drugs due to rigid conjugation either by the formation of covalent bond (either by ether or ester formation) or by salt formation with fatty acidsHighly potent hydrophilic drugs with the low therapeutic index can be conjugated easilyLDCs demonstrates high conjugation efficiency with the attached active moietiesIt can readily permit through the gastrointestinal tract (GIT).Possibility the avoidance of GI enzymatic or pH-dependent degradation.Promotes enhanced oral absorption of the bioactive via lymphatic uptake.Control/target drug release and its kinetics of conjugated compounds.Improved stability and bioavailability of many active pharmaceuticals ingredients.Feasibility of scaling such formulations to bulk industrial level.Fig. 1Three dimensional (3-D) schematic representation of LDCs structures

Such lipid-drug conjugated delivery matrices also possess significant therapeutic potential particularly in targeting especially the hydrophilic drugs at its site of action in severe protozoal infections as well \[[@CR4]\].

Necessary production procedure of LDCs at laboratory scale {#Sec2}
==========================================================

An insoluble synthetic bulk LDCs are initially either prepared by salt formation conjugated with fatty acids or by covalent linkage to form esters or ethers. Then this is processed with an aqueous surfactant or surfactant mixtures via adopting high shear homogenization techniques to achieve stabilized bulk LDCs formation \[[@CR4]\]. The detailed synthesis procedure of bulk LDCs manufacturing is systematically described in section "[Initial procedure of synthesizing bulk LDCs](#Sec4){ref-type="sec"}".

Basic ingredients required for the synthesis of LDCs and its NPs {#Sec3}
----------------------------------------------------------------

The lipid matrix can be comprised of various fatty acids (e.g., stearic acid, oleic acid, palmitic acid, myristic acid, lauric acid, caprylic acid, squalene etc.), acylglycerols/glycerides (glyceryl monostearate, glyceryl distearate, glyceryl tristearate, glyceryl behenate, glyceryl palmitostearate etc.), waxes (beeswax and cetyl palmitate), various biological membrane derived lipids (phospholipids and sphingomyelins) and mixtures of the same.

Various types of surfactants (including biological membrane lipids) can also be used for the preparation of bulk LDCs. The used surfactants can be lecithin, bile salts (sodium taurocholate, sodium glycolate), sterols (cholesterols), fatty acid ethoxylates, biocompatible non-ionic surfactants (Span −80, Tween 80, poloxamer-188, etc.) and maybe their mixtures which may act as stabilizer \[[@CR5]\]. Besides, ligands may be conjugated to this for promoting better tissue or cellular targeting.

Initial procedure of synthesizing bulk LDCs {#Sec4}
-------------------------------------------

LDCs can be synthesized in several ways. The hydrophilic drug can be converted to lipophilic prodrug by conjugating its free amino group (if available) with the free carboxylic acid group of fatty acids **(**Fig. [2](#Fig2){ref-type="fig"}**)** to form an amide linkage \[[@CR6], [@CR7]\]. Such reaction can be activated by the addition of some positive catalyst to accelerate the chemical reactions \[[@CR8]\]. Similarly, an insoluble synthetic bulk LDCs can also be synthesized by other covalent bonds between lipid and drug moieties via forming either ethers or esters linkage **(**Fig. [3](#Fig3){ref-type="fig"}**)**. It was already observed that drugs which lack carboxyl groups (such as phenytoin) allowing the direct formation of an ester bond with a diglyceride have to be bound to the glycerides by the addition of specific spacers like succinic acid \[[@CR9]\]. In other way, researchers were also synthesized LDCs with binary fatty acid salts of various drugs by dissolving the drug and fatty acid salts in different molar ratios in ethanol followed by consequent evaporation of ethanol under reduced pressure at room temperature \[[@CR10], [@CR11]\]. After the synthesis of bulk LDCs, it is generally being observed as complete lipophilic with a typical melting point range of approximately 50 to 100 °C reported elsewhere \[[@CR3]\].Fig. 2Schematic synthetic reaction scheme of formation of bulk LDCs via forming an amide bondFig. 3Schematic synthetic reaction scheme of formation of bulk LDCs via forming an ester bond

Formulation strategies for manufacturing bulk LDCs to LDC-NPs {#Sec5}
-------------------------------------------------------------

The procedure mentioned above depicted for the synthesis of bulk LDCs can be further transformed to LDC-NPs via adopting various formulation strategies or methodologies similar to our earlier chapter as we described the design of lipid nanoparticle formulations including SLNs and NLCs \[[@CR12]\]. However, LDC-NPs comprised of surfactant stabilized lipid-drug conjugated formulations where the used surfactants diminish the interfacial tension between the dispersed phase (especially water) and the synthesized formulations via enhancing the stabilization of the dispersed particles. Formation of LDC-NPs also causes reduction of particle size and thereby leading to strengthening their mean effective surface area with improved dissolution profile of the conjugated drugs. In Fig. [4](#Fig4){ref-type="fig"}, different methods are displayed for the preparation of LDC-NPs. Among which, the maximum number of LDC-NPs manufacturing scheme focused on cold high-pressure homogenization technique and solvent injection method due to their following inherent advantages:Feasibility of tailoring critical process parameters.Ease of scale-up.Uniform particle size distribution and less variable polydispersity indexImproved physical stability of the dispersion from the dispersant.Avoid temperature induced drug degradation and decomposition.Fig. 4Different methods employed in the preparation of LDC-NPs

### Cold high-pressure homogenization technique {#Sec6}

It is a straightforward, reliable and suitable homogenization technique for the manufacturing of LDC-NPs from its bulk LDCs. Although this method is entirely different from conventional hot or cold high-pressure homogenization method. Methodically, the synthesized bulk LDC is to be directly dispersed into the cold aqueous systems (kept at refrigerator before dispersion of bulk LDC) containing different surfactant mixture to prevent external partitioning of the conjugated drug into the external aqueous phase. The bulk LDC-surfactant containing aqueous dispersion is to be then further homogenized by high speed/shear homogenizer with a fixed rpm to achieve LDC-NPs with the desired particle size of interest \[[@CR10]\]. This method is particularly beneficial for water-loving and temperature-sensitive drugs as it serves as a whole lipidic carrier matrix for a hydrophilic drug for better drug targeting and secondly avoids temperature induced drug decomposition during high shearing. Also, the feasibility of scaling this method for the manufacturing in bulk industrial level and uniform controlling of the desired particle size is also feasible by adopting this method. Thus this method is being currently widely adopted especially in both food and pharmaceutical industry \[[@CR13]\].

### Solvent injection method {#Sec7}

This method is similar to solvent diffusion method. Generally, in this method lipids are to be dissolved in various polar organic solvents like methanol, isopropyl alcohol, acetone, etc. or its different ratio's solvent mixtures and then to be heated subsequently above the variable melting temperature of the used various lipid matrix. After melting, the melted lipid phase is to be then quickly injected into a surfactant-containing aqueous solution through an injection mode via syringe fitted with a needle, stirred and sonicated to form LDC-NPs. The formed LDC-NPs dispersion is to be then further lyophilized to get fine freeze-dried LDC-NPs \[[@CR8], [@CR13]\].

Detailed in vitro physicochemical characterizations {#Sec8}
===================================================

Due to the complex colloidal structure of the delivery system, they're in vitro characterization possesses is found to be a severe challenge. One can characterize the bulk synthesized LDCs and its NPs as a drug delivery systems in an independent way. Several essential evaluation parameters are associated with the evaluation establishments of LDCs and LDC-NPs. Those following parameters are systematically and separately depicted herein.

Evaluation of synthesized bulk LDC {#Sec9}
----------------------------------

### Percentage yield estimation {#Sec10}

The percent yield value of the bulk synthesized LDCs is to be calculated as total amounts of lipid and drug employed during its synthesis by using the following formula \[[@CR14]\].$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ \%\mathrm{yield}=\frac{\mathrm{Actual}\ \mathrm{amount}\ \mathrm{of}\ \mathrm{bulk}\ \mathrm{LDC}\ \mathrm{obtained}\ \mathrm{after}\ \mathrm{the}\ \mathrm{synthesis}}{\mathrm{Total}\ \mathrm{quantity}\ \mathrm{of}\ \mathrm{incorporated}\ \left(\mathrm{drug}+\mathrm{lipid}\right)}\times 100 $$\end{document}$$

### Thin layer chromatography (TLC) {#Sec11}

TLC is an advantageous technique to confirm the completion of the conjugation process at a different time of intervals. TLC studies have to be carried out for the preliminary confirmation of the formation of desired product after the process of conjugation. For TLC study, optimization of the suitable solvent system is utmost essential to confirm the desired conjugation process. Different ratios of the solvent systems have to be mixed for getting the proper separation of the synthesized, conjugated compound. TLC to be performed at a different time interval of a conjugation process along with the reactants with the process governed by the capillary action on silica gel plates. As time passes by the concentrations of the reactants got depleted, and the new conjugated compound tends to appear at different retention factor (R~f~) values. The completion of the reaction can be confirmed by obtaining a precise, sharp spot of the newly synthesized conjugated system where no other spot for the reactants at their respective R~f~ values should be seen. R~f~ values of any compound can be quantified by the distance traveled by the solute to the distance traveled by the solvent front and such values further confirmed by keeping them under ultra-violet (UV) lamp (especially for UV sensitive compound) or by using any substance-specific dyes for spot identification.

### UV-visible spectroscopy {#Sec12}

Majority of the pharmaceutical compound has their specific excitation and emission wavelength; thus there is fixed scanning wavelength (λ~max~) for each compound, and they were mentioned in several monographs. Completion of the conjugation reaction can also be judged by the help of UV-Visible spectroscopy by the depletion of the absorbance of the reactants after specific time periods. The number of reactants participating in the reaction can be measured by preparing a standard curve of that particular compound using various known concentrations. The time when the absorbance of the reactant/reactants becomes zero will reflect the completion of the reaction \[[@CR8]\].

### Percent conjugation efficiency (% CEE) {#Sec13}

UV-Visible spectroscopy can also determine % CEE by calculating the amount of unconjugated reactants from the initial reactant amount taken for the reactions at a particular wavelength, after confirming that all other components of the reaction mixture and their by-products did not interfere with the analysis of pristine drugs.

### Nuclear magnetic resonance (NMR) {#Sec14}

~1~H NMR is a very delicate technique to determine the proton environment of any compound. We can also elucidate the primary structure of the conjugated system by an accurate interpretation of the NMR spectra. NMR is an analytical tool from where we can get the information about the various types of protons present in the conjugate, the number of protons present form the signal strength and also the detailed knowledge of the adjacent proton environment from the splitting of the Spectra's. For understanding the spectra's one can perform the NMR spectroscopy for the reactants along with the final conjugated compound. For performing the NMR studies sample preparation is a significant step, and one must choose a particular solvent for solubilizing the reactants/compound. The compounds to be analyzed must be in a pure form, or it can generate unwanted peaks at the spectra which will cause difficulties for interpretation. The compounds are taken in a minute quantity and must be fully solubilized in the deuterated solvents \[[@CR15], [@CR16]\]. One can also perform ~13~C NMR for the interpretation of the carbon environment of the compound.

### Fourier transform infra-red (FTIR) spectral analysis {#Sec15}

FTIR is an analytical tool where the compound is subjected to generate specific vibrational frequency due to absorption of energy in the infra-red region. The intake of the energy results in producing a vibrational frequency which is definite for every molecule and thus from the vibrational frequency we can get a better idea of the different components present in that molecule. Therefore by accurate interpretation, we can estimate the various molecular components \[[@CR17], [@CR18]\]. Thus FTIR analysis will help us to elucidate the conjugation of the molecule and also it will serve as a side study for proper structure elucidation of the conjugate. Samples must be in pure form for the analysis. FTIR data can also reflect the purity of the compound and also one can judge the compatibility amongst the reactants, thus indicating the stability of the conjugated compound.

### Mass spectroscopy {#Sec16}

Mass spectroscopy is very important and delicate analytical tool, which will help us to elucidate the exact molecular mass of the compound along with possible molecular fragmentation. A complete interpretation of mass spectroscopy can confirm the precise structure of the conjugate. Various ionization techniques can be employed to determine the molecular mass. If the compound is sensitive, we can use matrix-assisted laser desorption/ionization (MALDI) as an analytical tool for elucidating the molecular formula of the conjugates along with its molecular mass.

Characterization of LDC-NPs {#Sec17}
---------------------------

After the systemic investigation based on these aforementioned observed evaluation parameters and confirmation of the formation of bulk LDCs, following essential characterizations have to be carried out to establish the formation of LDC-NPs from its bulk LDC further.

### Particle size {#Sec18}

The size of the particle plays a deciding role for proper GI uptake of the synthesized LDC-NPs and their systemic clearance by the reticuloendothelial system (RES). So it is always important to determine the size of the particle more accurately. It has already been reported that particle size less than 300 nm facilitates intestinal transport of the drug \[[@CR19]\]. Dynamic light scattering (DLS) or photon correlation spectroscopy (*PCS*) method is the more accurate and frequently used techniques for the measurement of particle size and its distribution analysis. DLS measures the intensity fluctuation of the scattered light caused by the Brownian motion of the developed LDC-NPs. However, nanometers to submicron range particle size can easily be measured by this technique \[[@CR20], [@CR21]\], which is enough to characterize the particle size of LDC-NPs. Interestingly, DLS or PCS does not measure the particle size directly, instead of that light scattering effects reflects the particle size, as particles are not always perfectly spherical \[[@CR22]\]. Therefore, additional techniques, for instance, light microscopy or electron microscopy can provide better contrast and a fast indication of the particle size and shape.

### Polydispersity index (PDI) {#Sec19}

PDI is very essential to determine the size distribution pattern of the fabricated LDC-NPs. Low PDI value reflects monodisperse particles population from the given LDC-NPs aqueous dispersion. As per many works of literature reports PDI value of less than 0.5 is considered as optimum value and the sample is to be regarded as monodisperse \[[@CR23], [@CR24]\]. The determination of such PDI values can be done by dynamic light scattering (DLS) method \[[@CR25]--[@CR27]\].

### Zeta potential (ZP) {#Sec20}

ZP measures the extent of electrostatic repulsion or attraction between the particles. It is an essential factor to impart stability of any formulation during storage. ZP can be applied to improve the formulation of dispersions, emulsions, and suspensions as ZP can cause dispersion, aggregation or flocculation. The repulsion between similarly charged particle is due to the ZP, i.e., more the ZP value (negative or positive), more the repulsion thus preventing the aggregation of the particles reflecting the stability of the nanoparticle dispersion. Whereas low ZP value leads to the aggregation/flocculation of the particles as the attraction exceeds the repulsion. ZP value of −30 mV is sufficient for stabilizing the conjugated nanodispersion \[[@CR28]\]. DLS method can be used for determining the ZP value of the conjugated nanodispersion \[[@CR25], [@CR27], [@CR29]--[@CR31]\].

### Electron microscopy analysis {#Sec21}

For determination of the shape and surface morphology of the synthesized LDC-NPs, scanning electron microscopy (SEM), transmission electron microscopy (TEM) and atomic force microscopy (AFM) techniques are considered as an essential tool. These techniques may also be used in determining the particle size and its size distribution analysis. Transmission of electrons from the sample surface is the working principle of SEM whereas TEM utilizes electron transport through the sample. SEM and TEM images can also provide an idea of the estimation of particle size and shape. For instance, many studies have been performed and showed spherical shaped nanoparticles \[[@CR22], [@CR26], [@CR32], [@CR33]\]. Field emission SEM (FE-SEM) is more sensitive than SEM as it allows detecting samples within nanometer range \[[@CR34]\].

### Atomic force microscopy (AFM) {#Sec22}

AFM technique can also be used for the characterization of LNFs \[[@CR35]\]. It has already been discussed that electron microscopy can provide a two-dimensional image of the synthesized LDC-NPs whereas AFM is capable of imaging a three-dimensional surface profile of the same tested conjugates. An atomic scaled sharp probe tip is inserted across the sample which provides the structural, mechanical, functional and topographical information of matrix surfaces ranged between nanometer to angstrom region \[[@CR5], [@CR13]\]. Depending on the nature of the sample and the serving force the probe can be dragged (contact method) or it can hover just above the sample (non-contact method) \[[@CR36]\]. Such microscopy technique can also analyze hydrated and non-hydrated samples containing solvents. Sometimes estimation of particle size can also be done via those electron microscopy techniques \[[@CR37]\].

### Differential scanning Calorimetry (DSC) {#Sec23}

DSC is an essential analytical tool which measures the glass transition temperature as a function of temperature. It reflects the melting and crystallization behavior of the synthesized LDC-NPs. As temperature increases, the crystal lattices breaks down, and data indicates the information about the polymorphism and crystal ordering \[[@CR38]--[@CR40]\]. DSC is also employed to observe physical changes, different lipid/drug modifications possess with various components of test melting point behavior such as a pristine drug, pristine lipid(s), physical mixtures of them, placebo LDC-NPs, etc. along with their thermal enthalpy values.

### X-ray powder diffraction (XRD) analysis {#Sec24}

XRD is a sophisticated analytical tool which is employed to know the crystalline characteristics of the synthesized LNPs with emphasis on optimized LDC-NPs formulations and other associated test components such as pristine drug, pristine lipid(s), physical mixtures of them, placebo LDC-NPs, etc. The utility of XRD analysis is that this instrument can quickly determine the crystallinity of the tested compounds based on their molecular lattice configuration \[[@CR41]\]. Determinations of the crystalline behavior of the samples are crucial as the lipid, and the conjugated drug may undergo some polymorphic transition which may lead to possible undesired physical instability during prolong storage conditions. Lipid crystallinity is also strongly correlated with incorporation or conjugation of the drug and its subsequent rate of release. The pattern of XRD diffractogram reflects the particular molecular arrangement of the lipid matrix, phase transition characteristics, and also predict lipid matrix and drug molecules structure \[[@CR42], [@CR43]\].

### Fluorescence spectroscopy {#Sec25}

Fluorescence spectroscopy can be employed for estimating the lipophilic molecular environment of the synthesized LDC-NPs by tagging with a specific lipophilic fluorescence marker or dye (e.g., Nile red or Coumarin-6). Fluorescent lipophilic dyes those absorption bands differ in size, shape, polarity, and intensity with the surrounding molecular environmental nature \[[@CR44], [@CR45]\]. The intensity of the peak will get increased as the particle size gets decreased so by this one can easily compare the particle size of the tested conjugated LDC-NPs samples. The peak intensity also gets increased with increase in lipophilic nature as the lipophilic marker will bind more with the compound.

### In vitro drug release study {#Sec26}

In vitro drug release from LDC-NPs can be determined by quantifying diffusion of released drug through a dialysis membrane method \[[@CR46]\]. To simulate in vivo gastric conditions, the in vitro drug release study is to be performed primarily in simulated intestinal fluid (preferably in the pH range of 6.8 to 7.4) for selective lymphatic uptake of the drug using dialysis sac method with a molecular weight cut-off of 10,000 to 12,000 Da. An accurate quantity of LDC-NPs has to be placed inside the dialysis sac, which is then clipped at both the ends. The whole sac is to be dipped in a suitable volume of dissolution test medium (alkaline pH) with proper stirring at fixed rotation under normal body temperature, i.e., 37 °C (±0.2 °C) for the entire course of the in vitro dissolution study. Aliquots sampling is to be carried out each at pre-set time intervals and immediately replaced by an equal volume of fresh dissolution medium to maintain sink conditions. Further aliquot samples are to be analyzed by suitable analytical instruments and proper conditions as well. The cumulative percent drug released at different intervals of time is to be compared to a standard calibration curve of various concentrations of drug generated by multiple analytical means like UV-visible spectroscopy, fluorescence microscopy, high performance liquid chromatography (HPLC) with suitable detection systems like photo-diode array (PDA), fluorescence spectroscopy, refractive index detection unit etc.

### Mechanism of drug release kinetics {#Sec27}

The mathematical modeling of drug release kinetics values from LDC-NPs can be determined by applying the obtained cumulative % release value data against different time plots fitted into various established release kinetics model to find the best fit based on regression coefficient value (preferably r^2^ = 0.999) among the following equations:$$\documentclass[12pt]{minimal}
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First-order rate kinetic equation (log cumulative percentage drug remaining to be released against time):$$\documentclass[12pt]{minimal}
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### Stability testing {#Sec28}

During prolonged storage period of conditions, the physical stability of LDC-NPs can be estimated by monitoring changes in ZP, mean particle size along with its PDI values, drug content values and by in vitro drug release profiles at different periods of sampling intervals. Determining values at different periods of sampling intervals is critical issues related to the stability of the newly synthesized conjugated compounds. This might govern elevation of particle size, dispersion gelation, and expulsion of drug from lipid crystalline lattice during the period of LDC-NPs storage. The phenomenon of gelation of dispersion occurs because of the lipid network formation and bridges between the spaces of the particles \[[@CR28]\].

### Statistical analysis {#Sec29}

After thorough in vitro physicochemical evaluation, the statistical treatment of the obtained data is much essential to establish the level of significance of the valued acquired data under suitable statistical treatment. Mean, and standard deviation value of each reproducible experimental data are to be used for statistical data analysis.

Role of LDCs in drug delivery applications {#Sec30}
==========================================

A lipophilic prodrug or LDCs is a burgeoning field of nanotechnology that has potential to deliver the drugs in specific target organ of interest. Some updated and exciting application of LDCs in drug delivery field is displayed in Table [1](#Tab1){ref-type="table"}**.** Taking advantage of lipid metabolic pathways, LDC is designed which could overcome the drug delivery problem and target specificity. The absorption of triglycerides takes place after hydrolysis into fatty acids and monoglycerides by lipase enzyme in the intestinal lumen. Pre-duodenal lipases include lingual and gastric lipases which are stable at acidic pH and hydrolyze the triglycerides at low pH. Hydrolysis of dietary triglycerides is very low by these two common enzymes. Thus, fatty acids and monoglycerides produced after hydrolysis are sufficient for emulsification which prepares the intestinal hydrolysis of lipids. The lipid catabolism in the intestine is mainly performed by phospholipase A~2~, pancreatic lipase and nonspecific esterase \[[@CR5], [@CR58]\].Table 1Examples of some interesting experiments carried out in respect to the formation and application of LDCs as drug delivery systemsLipids usedConjugationDrugs usedSignificant findingsReferencesStearic acid and oleic acid--Diminazene diaceturateTargets specific site with prolonged drug release. A possibility of increased uptake of diaminazene by low-density lipoprotein (LDL) receptor at the blood-brain barrier (BBB). It was observed that the formulated LDC nanoparticle avoids the hepatic uptake by plasma protein adsorption pattern. Plasma protein adsorption patterns indicate the avoidance of hepatic uptake with the possibility of increased uptake via the LDL receptors at the BBB.\[[@CR4]\]Stearic acidAmide groupCytarabineThe prepared LDC nanoparticles (NPs) showed smooth, spherical particle surface morphology without any aggregations, uniform particle size (136.80 ± 3.24 nm). In vitro, drug release pattern showed biphasic release, i.e., initial fast release almost 15% within one hr. Followed by prolonging release up to 72 h. LDC-NPs were more cytotoxic than Cyt solution at 48 h. LDC-NPs were found to be physically stable concerning size and zeta potential at the refrigerated condition for 90 days. Based on their findings. They concluded that LDC-NPs could be explored for treatment of meningeal leukemia owing to their ability to provide sustained drug release, stability and improved cytotoxicity in a leukemic EL-4 cell line.\[[@CR8]\]Different fatty acids for example stearic acid, oleic acid, myristic acid, lauric acid, caprylic acid and undecanoic acid.EsterPhenytoinLipid-phenytoin conjugates proved to be suitable substrates for pancreatic lipase in vitro due to the structural resemblance with triglycerides. It also showed significant improvement in the oral BA.\[[@CR9]\]Stearic acidAmino and hydroxyl groupDecitabineIn vitro release studies showed the initial burst release followed by a sustained release up to 24 h in phosphate buffer saline at pH -7.4 and the data were further studied using kinetic release models which revealed the first-order model as a best-fitting model. Ex vivo gut permeation study showed that there is a nearly fourfold increase in the permeation of the LDC-NPs containing lipid than that for the plain suspension of a drug under the same experimental conditions at the same time. The LDC-NPs of decitabine has higher permeability coefficients which finally lead to the improvement in the oral BA of decitabine. This system also protects the drug from chemical degradation and augmentation in permeability.\[[@CR10]\]Stearic acid and oleic acid--DiminazeneLDC-NPs, with 33% (wt/wt) drug loading capacity possess the potential to act as a delivery system for hydrophilic drugs like diminazene diaceturate and that further studies have to demonstrate the usability as a brain delivery system for the treatment of second stage Human African Trypanosomiasis (HAT). Transforming water-soluble hydrophilic drugs into LDC and formation of NPs allows prolonged drug release and targeting to specific sites by intravenous injection.\[[@CR11]\]Phospholipon 100H, Stearic acid and Palmitic acid,LipopeptideIsoniazidImproved cellular uptake and site-specific delivery of Isoniazid. Lipid monolayer model was used for penetration experiment to examine the membrane affinity of pal-T5-(INH)2 lipopeptide. The penetration lipopeptide is higher into mycolic acid-containing monolayer as compare to phospholipid.\[[@CR49]\]Ricinoleic acid, 12-hydroxy stearic acidlinked to a substrate for a membrane transporter/ receptor via a lipophilic raftAcyclovirBiotinylated lipid prodrugs of acyclovir possess enhanced affinity towards sodium-dependent multivitamin transporter (SMVT). These prodrugs appear to be potential candidates for the treatment of oral and ocular herpes virus infections, because of higher expression of SMVT on intestinal and corneal epithelial cells. Their novel prodrug design strategy may help in higher absorption of hydrophilic parent drug. Moreover, this novel prodrug design can result in higher cell permeability of hydrophilic therapeutics such as genes, siRNA, antisense RNA, DNA, oligonucleotides, peptides and proteins. This drug-loaded lipid conjugates also enhanced the BA and site specificity.\[[@CR50]\]Different fatty acids such as Stearic acid, palmitic acid and myristic acidAmine group of LMWH was conjugated with the carboxylic group of different lipidsLow Molecular Weight Heparin (LMWH)Significant enhancement of oral bioavailability as different fatty acids showed variable rate of increased bioavailability. The rate order of oral bioavailability was as follows: LMWH-Stearic acid \> LMWH-Palmitic acid \> LMWH-Myristic acid. Incorporation of these conjugates into SLNs significantly improved the bioavailability of LMWH after oral route administration with insignificant toxicity to different GIT tissue. This strategy holds promise for future applications of oral delivery of LMWH conjugates in the form of SLNs particularly for the treatment of cardiovascular disease.\[[@CR51]\]Squalene--CytarabineThe enhancement of the lipophilic character of cytarabine was obtained by the conjugation to the acyclic isoprenoid chain of squalene, to increase the affinity towards the phospholipid environment of a biological membrane as well as of lipophilic carrier.\[[@CR52]\]C~18~ fatty acid chainEsterGemcitabineShowed lower toxicity and promising efficacy in comparison to Gemzar®. This class of compounds with low toxicity may be further explored to circumvent the problems related with Gemzar®.\[[@CR53]\]Stearic acid--Diminazene and SIPI, a structural analogon to Diminazene (*p*,*p*^´^-diamidinodiazoaminobenzeneThe incubation of nanoparticles in sera of different species results in different adsorption patterns. These differences are difficult to estimate, especially when there is no reference as in the case of mouse plasma. This has to be taken into account when the data is to be correlated with in vivo experiments.\[[@CR54]\]Phospholipid--Ibuprofen and Valproic acidIncubation with phospholipase A~2~, a phospholipid which has palmitic acid at the SN~2~ position in glycerol moiety undergoes degradation while the presence of ibuprofen at the SN~2~ position resists the in vitro hydrolytic degradation of phospholipid. This was due to unnatural S configuration of ibuprofen.\[[@CR55]\]Various lipid-complexed--CamptothecinCamptothecin-lipid conjugate exhibit same antitumor and cytotoxicity properties as that of camptothecin without lipid-complex against multi-drug resistance positive and negative cancer cells. The camptothecin-lipid conjugate achieved the highest concentration at GIT whereas the drug itself alone reached the highest concentration in and pulmonary parenchyma. Besides, it was also reported that in-vivo activity such lipid-drug complex was found to be more potent than pristine drug against intraperitoneal L1210 and P338 leukemia.\[[@CR56]\]Lipidic and glycolipidic amino acidsLipidic amino acids with peptides and glycolipidic amino acids.CephalosporinOral absorption of poorly absorbed cephalosporin can be enhanced by conjugation of lipidic and glycolipidic amino acids. Such conjugation enhances the lipophilicity and oral uptake of cephalosporin which intensify the amount of drug in blood and at the site of action. Thus, it was suggested that lipidic amino acid and peptide conjugation of drugs could better alternative for enhanced oral bioavailability of other poorly absorbed drugs.\[[@CR57]\] .

Conclusion and future perspectives {#Sec31}
==================================

The collated valuable information reviewed and compiled in this article explored the various lipid-drug conjugates reported for increased oral bioavailability of the drug and site-specific drug targeting. Admixing of lipids with hydrophilic drugs imparted the lipophilicity of the drug in spite of several other benefits. This could lead to enhanced absorption and permeation of drug followed with the highest drug concentration at the site of action. Using the concept of the metabolic fate of fatty acids in our body, drug or molecule employed for linking with fatty acids which resemble the natural triglycerides and undergo same metabolic pathways as natural triglycerides by specific enzymes like phospholipase-A~2~, pancreatic lipase, and non-specific esterase. The released drug after enzymatic metabolism, it can reach the site of action in maximum concentration as compared to free drug. Thus, this conjugate system might be a potential approach for enhanced oral bioavailability of poorly water-soluble drug in various classes of therapeutic drugs. LDC is a highly versatile platform for poorly soluble drugs and considered as the best approach to get enhanced oral bioavailability of molecules facing the limited oral absorption. Many such drugs are placed in the BCS class II and IV. Creative lipid drug conjugates of these drug molecules in finished formulations may present an improved pharmacokinetic profile in the human body. The approach may be implemented in diverse medicine such as phytomedicine which could be delivered in this new delivery for site-specific and targeted drug delivery. Lipid is naturally digested by the human body and required no much toxicity data to ensure safety issues. Many publications, abstracts, reviews, and patents are available since last decades. This reflected the drawn attention of pharmaceutical scientist involved in research in this domain. There must be a liaison between research academia and pharmaceutical industries to take up this drug delivery approach for successful formulation with improved BA. For comparison, these delivery approaches are considered suitable carrier than other polymeric systems as safer in term of toxicity. It has several distinct advantages such as protection of thermosensitive drug, protection of drug from enzymatic degradation and enhanced oral absorption which result into increased oral absorption. The shelf life stability, sterilization for a parenteral product of lipid-based formulations and large-scale production of lipid drug conjugates are remaining challenges of this carrier system which need to be investigated shortly.
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LNFs

:   Lipid Nanoparticle Formulations

LDCs

:   Lipid-drug Conjugates

NPs

:   Nanoparticles

GIT

:   Gastrointestinal Tract

ZP

:   Zeta Potential

PDI

:   Polydispersity Index

BA

:   Bioavailability

BCS
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